Applicability is limited by the lack of precise quantification of late gadolinium enhancement burden that may allow for more nuanced risk stratification. Some stud- ies suggested that a threshold effect exists, with extensive LV and RV involvement being a particu- larly high-risk feature.S7.6-7,S7.6-8 However, late gad- olinium enhancement can be present even if the LVEF is >50% and was associated with a risk of death or VT of 4.9% per year compared to 0.24% per year when late gadolinium enhancement was absent in 1 observational study.S7.6-7 PET for assess- ing inflammation and scar is also being increas- ingly used, but data are limited. In 1 report, the Figure 8. prevention of SCD in patients with cardiac sarcoidosis. Colors correspond to Class of Recommendation in Table 1. See Section 7.6 for discussion. *ICD candidacy as determined by functional status, life expectancy, or patient preference. For recurrent sustained monomorphic VT, refer to Figure 2. CEP indicates electrophysiological; GDMT, guideline-directed management and therapy; ICD, implantable cardioverter-defibrillator; LVEF, left ventricular ejection fraction; MRI, magnetic resonance imaging; PET, positron emission tomography; SCA, sudden cardiac arrest; SCD, sudden cardiac death; VA, ventricular arrhythmia; and VT, ventricular tachycardia. CLINICAL STATEMENTS AND GUIDELINES presence of inflammation and RV involvement on PET scanning was associated with increased risk of death or e g of relatives.S7.6-10 Electrophysiological studies in a series of 76 patients with evidence of cardiac sarcoid found that 11% had inducible VT. During a median follow-up of 5 years, 75% of patients with inducible VT had spontaneous VT or death compared with 1.5% of those who did not have inducible VT.S7.6-18 3. 